Mammalian Platform Process Development & Scale Up

Improving process yields of recombinant proteins, monoclonal antibodies (mAbs) and biosimilars
Cobra continues to develop robust and scalable processes for protein expression, with media development and optimisation (animal component free), and the maximisation of harvest parameters, improving both the quality and productivity of our customer's antibody products.
We have developed an efficient platform process for antibody production that reduces development time and, when combined with our maxXpress service, provides significantly improved yields.

NEW FOR 2014: 1000L HyClone Single-Use Bioreactor (SUB) 

Other Mammalian Protein Services...

In order to provide complete functionality, this web site needs your explicit consent to store browser cookies. If you don't allow cookies, you may not be able to use certain features of the web site. It is recommended that you allow all cookies. Allow all cookies